Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study
Centre Hospitalier Régional d'Orléans
600 participants
Mar 11, 2025
OBSERVATIONAL
Conditions
Summary
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.
Eligibility
Inclusion Criteria1
- All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection
Exclusion Criteria6
- Cystic fibrosis
- P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy
- Protected person (under guardianship or curatorship)
- Persons under court protection
- Persons deprived of liberty
- Opposition expressed for participation in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(48)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06738771